trending Market Intelligence /marketintelligence/en/news-insights/trending/JBSj0kQmLgVoFp71spgBFg2 content esgSubNav
In This List

Eisai, Purdue Pharma seek US FDA approval for sleep disorder treatment

Blog

Gauging Supply Chain Risk In Volatile Times

Blog

Insight Weekly: Banks' efficiency push; vacuuming carbon; Big Pharma diversity goals

Blog

The Future of Risk Management Digitization in Credit Risk Management

Blog

Climate Credit Analytics: Diving into the model


Eisai, Purdue Pharma seek US FDA approval for sleep disorder treatment

Eisai Co. Ltd. and Purdue Pharma LP are seeking U.S. Food and Drug Administration approval for lemborexant as a treatment for insomnia, a sleep disorder.

The new drug application submitted to the regulator was based on the results of two phase 3 trials called Sunrise 1 and Sunrise 2, which enrolled about 2,000 patients.

Lemborexant works by acting the orexin neurotransmitter system, which regulates a person's wakefulness.

Tokyo's Eisai and Stamford, Conn.-based privately held company Purdue Pharma are jointly developing the therapy for sleep-wake disorders. Lemborexant is also slated for a phase 2 study in patients with irregular sleep-wake rhythm disorder and mild to moderate Alzheimer's dementia.